US2022249409A1PendingUtilityA1

Early administration of low-dose colchicine after myocardial infarction

68
Assignee: INST DE CARDIOLOGIE DE MONTREALPriority: Nov 15, 2019Filed: Apr 27, 2022Published: Aug 11, 2022
Est. expiryNov 15, 2039(~13.3 yrs left)· nominal 20-yr term from priority
Inventors:Jean-Claude Tardif
A61P 9/10A61K 31/165
68
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to colchicine for use in a method of treating a patient after having a myocardial infarction (MI), the method including initiating the administration of colchicine at a daily low dose to the patient within about 3 days of the MI.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating a patient after having a myocardial infarction (MI), the method comprising initiating the administration of colchicine at a daily low dose to the patient within about 3 days of the MI. 
     
     
         2 . The method according to  claim 1 , wherein percutaneous coronary intervention was performed for treating the patient's MI. 
     
     
         3 . The method according to  claim 1 , wherein the patient was prescribed a medication. 
     
     
         4 . The method according to  claim 3 , wherein the medication is an antiplatelet agent. 
     
     
         5 . The method according to  claim 3 , wherein the medication is aspirin. 
     
     
         6 . The method according to  claim 3 , wherein the medication is a statin. 
     
     
         7 . The method according to  claim 1 , wherein the patient is at a lower risk of a cardiovascular event, relative to a patient not being administered colchicine. 
     
     
         8 . The method according to  claim 7 , wherein the cardiovascular event is an ischemic cardiovascular event. 
     
     
         9 . The method according to  claim 7 , wherein the cardiovascular event is resuscitated cardiac arrest. 
     
     
         10 . The method according to  claim 7 , wherein the cardiovascular event is myocardial infarction. 
     
     
         11 . The method according to  claim 7 , wherein the cardiovascular event is stroke. 
     
     
         12 . The method according to  claim 7 , wherein the cardiovascular event is urgent hospitalization for angina requiring coronary revascularization. 
     
     
         13 . The method according to  claim 1 , wherein the patient has atherosclerotic coronary artery disease. 
     
     
         14 . The method according to  claim 1 , wherein the administration of colchicine is initiated upon assessment in (a) an emergency department (ED), (b) the hospital, or (c) a medical office setting. 
     
     
         15 . The method according to  claim 1 , wherein the colchicine is in the form of a tablet. 
     
     
         16 . The method of  claim 15 , wherein the tablet is coated. 
     
     
         17 . The method of  claim 16 , wherein the tablet is film-coated. 
     
     
         18 . The method according to  claim 1 , wherein the colchicine is administered at 0.3 to 0.7 mg. 
     
     
         19 . The method according to  claim 18 , wherein the colchicine is administered at 0.4 to 0.6 mg 
     
     
         20 . The method according to  claim 16 , wherein the colchicine is administered at 0.5 mg. 
     
     
         21 . The method according to  claim 9 , wherein the colchicine is administered at 0.5 mg. 
     
     
         22 . The method according to  claim 10 , wherein the colchicine is administered at 0.5 mg. 
     
     
         23 . The method according to  claim 11 , wherein the colchicine is administered at 0.5 mg. 
     
     
         24 . The method according to  claim 12 , wherein the colchicine is administered at 0.5 mg. 
     
     
         25 . The method according to  claim 1 , wherein the colchicine is administered once, twice or three times a day. 
     
     
         26 . The method according to  claim 25 , wherein the colchicine is administered once per day. 
     
     
         27 . The method according to  claim 1 , wherein the colchicine is administered without pre-loading the patient with colchicine. 
     
     
         28 . The method according to  claim 1 , wherein the patient is an adult human. 
     
     
         29 . A method of reducing the risk of a stroke in a patient after having an MI, the method comprising initiating the administration of colchicine at a daily low dose to the patient within about 30 days of an MI. 
     
     
         30 . The method according to  claim 29 , wherein the method comprises administering colchicine within 4 to 7 days of the MI.

Join the waitlist — get patent alerts

Track US2022249409A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.